← Back to patent-cliff list
AUR-103
Tier C — Watch / tradeAUR-103
Aurigene
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CD47
Indications (approved)：Neuroendocrine tumour, Leukaemia, Non-Hodgkin lymphoma, Myelodysplastic syndrome, Acute myeloid leukaemia, Solid tumour, 食管胃结合部肿瘤, Gastric cancer
Regional status
US
Phase II
2026-06-30
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AUR-103?
Approved indications include: Neuroendocrine tumour, Leukaemia, Non-Hodgkin lymphoma, Myelodysplastic syndrome, Acute myeloid leukaemia, Solid tumour, 食管胃结合部肿瘤, Gastric cancer.
When does the AUR-103 patent expire?
No public expiry year is available for AUR-103 yet; this page updates once verified.
How do I get a quote for AUR-103 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30